APA (7th ed.) Citation

Y, K., GE, J., S, A., L, H., CA, A., A, W., . . . T, C. (2018). A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood advances, 2(8), 848. https://doi.org/10.1182/bloodadvances.2018017517

Chicago Style (17th ed.) Citation

Y, Kovtun, et al. "A CD123-targeting Antibody-drug Conjugate, IMGN632, Designed to Eradicate AML While Sparing Normal Bone Marrow Cells." Blood Advances 2, no. 8 (2018): 848. https://doi.org/10.1182/bloodadvances.2018017517.

MLA (9th ed.) Citation

Y, Kovtun, et al. "A CD123-targeting Antibody-drug Conjugate, IMGN632, Designed to Eradicate AML While Sparing Normal Bone Marrow Cells." Blood Advances, vol. 2, no. 8, 2018, p. 848, https://doi.org/10.1182/bloodadvances.2018017517.